Delta wave activity disruption during sleep may be a useful metric to identify those at an increased risk for cardiovascular disease and mortality, a new study suggested.
Zolpidem and behavior therapy each reduce daytime symptoms of insomnia such as fatigue, functional impairments, and depressive symptoms, data suggested.
A recent study assessed a combination of aroxybutynin, which has an antimuscarinic effect, and atomoxetine, which has a noradrenergic effect, in treating OSA.